Johan Widmark | 2025-08-29 08:00 READ REPORT IN PDF In Q2, Prolight reported initial positive data from its ongoing whole

Johan Widmark | 2025-06-18 08:00 READ REPORT IN PDF Key milestone for readiness Prolight has reported positive interim results from

Johan Widmark | 2025-05-23 08:00 READ REPORT IN PDF Strong insider commitment signals confidence As expected, Prolight has now announced

Following the many recent grants, notices of allowance and intention to grant patents in Europe and the US, and the

The recent acquisition of Norwegian point-of-care diagnostics platform SpinChip by bioMérieux for EUR 138 million underscores the growing interest, strategic

The arrival of the first commercial prototype instruments for Prolight’s Psyros Point of Care (POC) system marks an important development

Prolight continues to make progress with its proprietary Psyros platform, with a pre-validation study, including fresh blood samples from 120

Supported by the latest troponin data generated from whole blood samples on the final commercial cartridge design, Prolight is now

Prolight’s report for Q1’24 did not reveal any particular surprises. The positive SEK 5.6m revision to the FY’23 result stemming

There has been a somewhat mixed news flow from Prolight after the close of Q1’24. The finalization of the cartridge